Antithrombin attenuates myocardial dysfunction and reverses systemic fluid accumulation following burn and smoke inhalation injury: a randomized, controlled, experimental study by Rehberg, S. (Sebastian) et al.
RESEARCH Open Access
Antithrombin attenuates myocardial dysfunction
and reverses systemic fluid accumulation
following burn and smoke inhalation injury:
a randomized, controlled, experimental study
Sebastian Rehberg1,2*, Yusuke Yamamoto1, Eva Bartha1, Linda E Sousse1, Collette Jonkam1, Yong Zhu1,
Lillian D Traber1, Robert A Cox3,4, Daniel L Traber1,4 and Perenlei Enkhbaatar1,4
Abstract
Introduction: We hypothesized that maintaining physiological plasma levels of antithrombin attenuates myocardial
dysfunction and inflammation as well as vascular leakage associated with burn and smoke inhalation injury.
Therefore, the present prospective, randomized experiment was conducted using an established ovine model.
Methods: Following 40% of total body surface area, third degree flame burn and 4 × 12 breaths of cold cotton
smoke, chronically instrumented sheep were randomly assigned to receive an intravenous infusion of 6 IU/kg/h
recombinant human antithrombin (rhAT) or normal saline (control group; n = 6 each). In addition, six sheep were
designated as sham animals (not injured, continuous infusion of vehicle). During the 48 h study period the animals
were awake, mechanically ventilated and fluid resuscitated according to standard formulas.
Results: Compared to the sham group, myocardial contractility was severely impaired in control animals, as
suggested by lower stroke volume and left ventricular stroke work indexes. As a compensatory mechanism, heart
rate increased, thereby increasing myocardial oxygen consumption. In parallel, myocardial inflammation was
induced via nitric oxide production, neutrophil accumulation (myeloperoxidase activity) and activation of the p38-
mitogen-activated protein kinase pathway resulting in cytokine release (tumor necrosis factor-alpha, interleukin-6)
in control vs. sham animals. rhAT-treatment significantly attenuated these inflammatory changes leading to a
myocardial contractility and myocardial oxygen consumption comparable to sham animals. In control animals,
systemic fluid accumulation progressively increased over time resulting in a cumulative positive fluid balance of
about 4,000 ml at the end of the study period. Contrarily, in rhAT-treated animals there was only an initial fluid
accumulation until 24 h that was reversed back to the level of sham animals during the second day.
Conclusions: Based on these findings, the supplementation of rhAT may represent a valuable therapeutic
approach for cardiovascular dysfunction and inflammation after burn and smoke inhalation injury.
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consumption, tumor necrosis factor, left ventricular dysfunction
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Introduction
Burn- and smoke inhalation-induced shock not only
implies hemodynamic instability and vascular leakage
but also severe myocardial dysfunction [1], which
already occurs two hours after the injury [2]. Contrary
to septic cardiomyopathy [3], for example, the clinical
relevance of burn- and smoke-induced myocardial dys-
function is only poorly recognized. However, there is a
significant correlation between left ventricular dysfunc-
tion and in-hospital mortality of critically burned
patients [4]. In addition, myocardial stress caused by
burn injuries persists for up to three years, thereby also
influencing long-term outcome [5]. Therefore, effective
treatment strategies for burn- and smoke-induced myo-
cardial dysfunction are warranted.
The proposed pathogenesis of burn- and smoke-induced
myocardial dysfunction is based on inflammatory mechan-
isms, including activation of the p38-mitogen-activated
protein kinase (p38-MAPK) pathway as well as production
of tumor necrosis factor alpha (TNF-a) and nitric oxide
(NO) [6-8]. The plasma-derived glycoprotein antithrombin
III (AT) has been shown to reduce neutrophil activation
[9] and to attenuate all of these inflammatory cascades in
lung injury, for example [10-12]. However, potential bene-
fits of AT on cardiovascular inflammation and dysfunction
following burns and smoke inhalation have not been
investigated, yet. A second rationale for the use of AT in
these patients is an AT deficiency following burn injuries
[13], that represents an independent predictor of length of
hospital stay and mortality [14,15].
Accordingly, we hypothesized that maintaining physio-
logical plasma levels of AT reduces myocardial inflam-
mation and attenuates cardiovascular dysfunction
associated with burn and smoke inhalation injury.
Therefore, the present prospective, randomized, con-
trolled laboratory experiment was designed to elucidate
the effects of an intravenous infusion of recombinant
human AT (rhAT) on myocardial neutrophil accumula-
tion, activation of the p38-MAPK pathway, myocardial
TNF-a secretion and systemic NO production as well as
cardiovascular hemodynamics and systemic fluid accu-
mulation in an established ovine model [16,17].
Materials and methods
The study was approved by the Animal Care and Use
Committee of the University of Texas Medical Branch
at Galveston and conducted in compliance with the
guidelines of the National Institutes of Health.
Instrumentation and surgical procedures
Eighteen female sheep were anesthetized and instrumen-
ted for chronic hemodynamic monitoring using an
established protocol [16,17]. Details are provided in
Additional file 1, Materials and methods.
Experimental protocol
Following baseline measurements (BL) in the healthy
sheep, a tracheostomy was performed and a urinary
bladder catheter was placed under deep anesthesia.
Twelve animals were then subjected to 40% of total
body surface area third degree flame burn and 4 × 12
breaths of cold cotton smoke under deep anesthesia
using an established protocol [16,17]. The arterial car-
boxyhemoglobin level was determined immediately after
smoke inhalation to quantify the degree of injury.
Although third degree burns are considered painless,
0.03 mg buprenorphine i.v. was administered before the
burn and every 12 h subsequently to provide analgesia
for the edges of the burn area, which may be second-
degree burns. The sheep were then randomly assigned
to the control group (injured, continuous infusion of
vehicle (NaCl 0.9%), n = 6) or the rhAT group (injured,
continuous infusion of 6 IU/kg/h rhAT (GTC Biothera-
peutics Inc., Framingham, MA, USA) from 1 h post
injury until the end of the 48-h study period, n = 6).
During the experiment the investigators were unaware
of the animal’s group assignment. Six animals were
assigned to the sham group (not injured, continuous
infusion of vehicle (NaCl 0.9%)). Due to the obvious
lack of burn injury, this group assignment could not be
blinded.
All animals were mechanically ventilated with a tidal
volume of 15 mL/kg and a positive end-expiratory pres-
sure of 5 cmH2O throughout the entire experiment. In
this context, it is important to consider the study design
and the physiological differences between sheep and
humans (see in detail Additional file 1, Materials and
methods). The inspiratory oxygen fraction was set at
100% for the first three hours post injury, and was then
adjusted to maintain oxygenation (arterial oxygen
saturation >90%, partial pressure of oxygen >90 mmHg),
whenever possible. The respiratory rate was adjusted
according to individual blood gas analyses to ensure
normocapnia.
Resuscitation was performed with lactated Ringer’s
solution according to the Parkland formula (4 mL/kg/%
burned body surface area within 24 h) [18]. To compen-
sate for the initial fluid loss, sheep received one half of
the total calculated amount for 24 h within the first 8 h
after injury. At the end of the 48-h study period, sheep
were deeply anesthetized with ketamine (15 mg/kg) and
killed by injection of 60 mL of saturated potassium
chloride.
Hemodynamic monitoring and laboratory analyses
Hemodynamic measurements, analyses of blood samples
for gas tensions, plasma levels of AT and NO, protein con-
centration, oncotic pressures, variables of plasmatic coagu-
lation and creatinine (plasma and urine) were performed
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at specific time points. Details are provided in Additional
file 1, Materials and methods.
Immunohistochemical analysis and Western blots
Samples from the left ventricle (anterior wall) were used
for quantification of myeloperoxidase activity, p38-MAPK,
TNF-a and interleukin-6 (IL-6). Myeloperoxidase activity
was determined using a commercially available assay
(Myeloperoxidase Activity Assay, Northwest Life Science
Specialties, Vancouver, BC, Canada) according to the
manufacturer’s protocol. Details are provided in Addi-
tional file 1, Materials and methods.
Statistical analyses
Sigma Stat 3.1 software (Systat Software, Inc., San Jose,
CA, USA) was used for statistical analyses. Analysis of
variance on ranks methodologies appropriate for non-
normally distributed variables with repeated measures
were used. Each variable was analyzed separately for dif-
ferences among groups, differences across time, and for
group by time interaction. After confirming the signifi-
cance of different group effects over time, post hoc pair-
wise comparisons among groups were performed using
the Student-Newman-Keuls procedure to adjust for the
elevated false positive rate found otherwise in multiple
testings. Finally, a rank sum test was applied to compare
values at each time point. Western blot analyses and
myeloperoxydase activity were compared with the rank
sum test. Data are expressed as median with interquar-
tile range (25th; 75th). Differences were considered as
statistically significant when P was less than 0.05.
Results
Baseline characteristics
The mean body weight of the sheep was 33 kg (29; 38).
There were no differences among study groups in any
of the investigated variables at BL. Carboxyhemoglobin
values after smoke inhalation, as an index of the severity
of injury, did not differ among groups (control: 69% (58;
74) vs. rhAT: 73% (58; 80), P = 0.610).
Cardiovascular hemodynamics
Stroke volume index (SVI; 24 to 48 h: P <0.05 vs. BL and
24 to 48 h: P <0.05 vs. sham, Figure 1a) and left ventricular
stroke work index (LVSWI, 12 to 48 h: P <0.05 vs. BL and
24 to 48 h: P <0.05 vs. sham, Table 1) decreased by about
50% vs. BL in the control group within 24 h. In these ani-
mals, cardiac index was maintained (no statistical differ-
ences vs. BL) by a progressive increase in heart rate (HR; 6
to 48 h: P <0.05 vs. BL and 12 to 48 h: P <0.001 vs. sham,
Figure 1b). Myocardial oxygen consumption [19] increased
significantly (24 to 48 h: P <0.05 vs. BL and 6 h, 24 to 48 h:
P <0.05 vs. sham, Figure 2a). rhAT treatment attenuated
the decreases in SVI (24 to 48 h: P <0.05 vs. control) and
LVSWI (24 to 48 h: P < 0.05 vs. control each), resulting in
a lower HR and oxygen consumption than in control ani-
mals (12 to 48 h: P < 0.05 each). With one exception at
24 h (rhAT and sham vs. control: P <0.05 each), there
were no significant differences in cardiac index between
study groups (Table 1). Right ventricular stroke work
index was lower in control animals as compared to sham
from 24 to 36 h (P <0.05 each). Left atrial pressure (LAP)
increased over time in the control group (24 to 48 h: P <
0.05 vs. BL each). rhAT infusion was associated with a
lower LAP (48 h: P = 0.016 vs. control). Similarly, central
venous pressure (CVP) increased in control animals (24 to
36 h: P < 0.05 vs. BL; P < 0.05 vs. sham), whereas CVP did
not increase in rhAT-treated animals (P = 0.01 vs. control
at 36 h). Left ventricular contractility, expressed as a corre-
lation of LVSWI and LAP, an index of left ventricular pre-
load (Figure 2b), was markedly impaired in the control
group, whereas contractility in rhAT-treated animals was
comparable to sham animals.
Vascular leakage and fluid accumulation
Vascular leakage was evidenced in control animals by an
increased hematocrit (36 h: P = 0.017 vs. BL and P =
0.048 vs. sham, Table 2) in parallel with decreases in
plasma protein concentration and plasma oncotic pres-
sures (6 to 48 h: P < 0.05 vs. BL and 6 to 48 h: P < 0.05
vs. sham, Table 2). Accordingly, cumulative net fluid
balance progressively increased resulting in a systemic
fluid accumulation of about 4,000 mL in the control
group at 48 h (12 to 48 h: P < 0.05 vs. sham, Figure 3a).
In rhAT-treated animals, there was an initial decrease in
plasma protein concentration and plasma oncotic pres-
sures without any further progression afterwards (P <
0.01 vs. BL and P <0.05 vs. sham each). Hematocrit did
not change compared with BL or sham animals in the
rhAT group. Cumulative net fluid balance initially
increased in rhAT-treated animals from 12 to 24 h (P <
0.05 vs. sham), but came back to sham level at 48 h
(P = 0.004 vs. control, Figure 3a).
Urine flow in control animals progressively decreased
over the study period and was lower than in the sham
group (6 to 48 h: P <0.05 each, Table 2). In the rhAT
group, urine flow was lower than in sham animals from
6 to 12 h (P <0.05 each), but higher than in control ani-
mals from 24 to 48 h (P <0.05 each).
Gas exchange and global oxygen transport
Arterial oxygen saturation did not differ from BL in sham
and rhAT-treated animals over the 48-h study period. In
the control group arterial oxygen saturation was lower
than BL and sham animals from 24 to 48 h (P < 0.05
each). Variables on pulmonary gas exchange and ventila-
tion are depicted in detail in Additional file 2, Table S1.
There were no persistent differences in variables of global
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oxygen transport between the study groups (see Addi-
tional file 2, Table S1).
Laboratory analyses
In control animals burn and smoke inhalation was asso-
ciated with an immediate decrease of AT plasma concen-
trations (6 to 48 h: P < 0.05 vs. BL) resulting in lower
values than in sham animals (6 to 48 h: P < 0.05 each,
Table 2). The continuous infusion of rhAT prevented
this decrease and kept AT plasma concentrations at BL
level and higher than in control animals (6 to 48 h: P <
0.05 each).
No significant differences in activated clotting time,
activated partial thromboplastin time and platelet count
could be shown over time or between study groups.
There was an increase in prothrombin time in both
injured groups as compared to BL (36 to 48 h: P < 0.05)
and sham animals (12 to 48 h: P < 0.05); however, with-
out statistical differences between the control and the
rhAT group (see Additional file 2, Table S1).
There were no significant differences between study
groups in creatinine clearance during the study period
(Table 2).
In control animals, plasma levels of nitrates and nitrites
(NOx) increased five-fold within 12 h (6 to 12 h: P < 0.05
vs. BL and sham each). Then, NOx plasma levels
decreased from 12 to 24 h, before they increased again
from 24 to 48 h (P <0.05 vs. BL and sham each). rhAT
infusion attenuated the first increase (12 h: P = 0.032 vs.
control) and prevented the second increase of plasma
NOx compared with control animals (36 to 48 h: P <
0.05 vs. control, Figure 3b).
Immunohistochemical analyses and Western blots
Immunohistochemical analyses of myocardial tissues
revealed a significant increase in myeloperoxydase activ-
ity in control vs. sham animals (P = 0.026, Table 3). In
rhAT-treated animals, myeloperoxidase activity was
lower than in the control group (P = 0.041).
Western blots performed in myocardial tissues showed
higher concentrations of p38-MAPK in the control vs.
the sham group (P = 0.028, Table 3). In addition, there
was an increase in myocardial concentrations of the
inflammatory cytokines TNF-a and IL-6 in control vs.
sham animals (P < 0.05 each, Table 3). Contrarily, in the
rhAT group concentrations of p38-MAPK (P = 0.01) as
well as TNF-a (P = 0.046) and IL-6 (P = 0.038), were
lower than in control animals.
Discussion
The major findings of the present study are that 1) burn
and smoke inhalation injury was associated with myo-
cardial dysfunction and inflammation, and that 2) a con-
tinuous infusion of rhAT attenuated the impairment of
myocardial contractility, 3) reduced myocardial inflam-
mation, 4) limited NO production, and 5) reversed sys-
temic fluid accumulation 6) without compromising
plasmatic coagulation in a clinically relevant ovine
model.
Burn- and smoke-induced myocardial dysfunction is
typically characterized by an impaired left ventricular
contractility [1,20]. In the present study, a reduced myo-
cardial function in control animals was evidenced by
lower SVI and LVSWI as compared to BL and sham ani-
mals. Although no direct measurement of contractility
Figure 1 Stroke volume index (a) and heart rate (b). *P < 0.05 vs. baseline; #P < 0.05 vs. sham; † P < 0.05 vs. control; data are represented as
box plots with median and interquartile range (25th; 75th); n = 6 per group. BL, baseline; HR, heart rate; rhAT, recombinant human antithrombin
III; SVI, stroke volume index.
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was performed, the Starling-based relation of LVSWI
with the individual preload at this time (LAP) highly sug-
gests an impaired myocardial contractility in the control
vs. sham group. Notably, the time courses for SVI and
HR in control animals nicely demonstrate the “two-hit”
character of the injury [21]: the first one, immediately fol-
lowing the injury, is caused by the burn-induced shock
and the associated systemic inflammatory response syn-
drome (SIRS). The second one is most probably attributed
to an inflammatory response to the smoke inhalation
usually occurring 24 h post injury [21,22].
As a compensatory mechanism, HR increased in control
animals thereby maintaining cardiac output. However,
myocardial oxygen consumption, as suggested by the
(heart) rate-(mean arterial) pressure product [19], was
consistently higher than in sham animals. In the acute
phase of the injury, this increased myocardial oxygen con-
sumption and the impairment of myocardial function
potentially aggravate burn-induced shock as well as the
associated SIRS, thereby eventually promoting multiple
organ failure. Previously, burn- and smoke-induced myo-
cardial dysfunction was thought to be transient and to
resolve after successful treatment of the originating trauma
[2]. Meanwhile, there is convincing evidence that it also
influences long-term outcome. An increased HR and myo-
cardial oxygen consumption, for example, were found to
be present even three years after burn trauma in children
[5,23]. Hypovolemia as a cause of reduced SVI and
increased HR in the present study seems unlikely within
the first 24 h, because in this case ventricular filling pres-
sures as well as mean arterial pressure and cardiac index
would have been decreased in control animals.
rhAT infusion markedly improved contractility, as
suggested by higher SVI and LVSWI values as compared
to control animals. In accordance with these findings,
HR and myocardial oxygen consumption were signifi-
cantly lower in rhAT-treated than in control animals.
Whereas beneficial effects of AT on pulmonary gas
exchange [10] and wound healing [24] in patients suffer-
ing from burn and smoke inhalation have been reported
before, this is the first time that a therapeutic effect of
AT on myocardial function is described.
Since “cardiac molecular signalling after burn trauma”
involves several inflammatory pathways [7], the anti-
inflammatory effects of rhAT represent a potential
mechanism of action. As part of the burn- and smoke-
induced SIRS, there is a pronounced activation of neutro-
phils leading to transendothelial migration into the organs
and promotion of inflammatory cascades, like NO produc-
tion and p38-MAPK pathway activation [6-8]. Neutrophil
accumulation in heart tissues was suggested by an increase
in myeloperoxidase [25] in control vs. sham animals that
was attenuated by rhAT. This finding is well explained by
the interaction of AT with the syndecan-4 receptor result-
ing in reduced neutrophil activation and chemotaxis
[9,26].
In addition, activation of the p38-MAPK cascade plays
a central role in burn-induced myocardial dysfunction
[6,7,27-29]. It regulates apoptosis of cardiomyocytes in
the early stage after severe burns [6,28] and promotes
inflammation by increasing the production of TNF-a
and downstream cytokines like IL-6 [1,6,27], both being
significantly increased in the control vs. the sham group
Table 1 Variables of cardiovascular hemodynamics
Variable Time point sham control rhAT
CI BL 6.1 (5.6; 6.7) 5.9 (5.7; 6.7) 6.8 (6.1; 7.8)
(L/min/m2) 6 h 6.7 (6.0; 7.5) 6.2 (5.3; 7.2) 6.7 (5.6; 7.5)
12 h 6.9 (6.4; 7.0) 6.0 (4.7; 7.4) 7.8 (6.9; 8.4)
24 h 7.1 (6.6; 7.4) 5.5 (5.0; 5.6)# 8.0 (6.8; 8.8)†
36 h 6.2 (5.4; 7.3) 5.6 (5.3; 6.4) 6.7 (6.3; 7.8)
48 h 6.5 (6.4; 6.9) 4.5 (4.4; 7.2) 6.7 (5.8; 7.7)
MAP BL 97 (93; 98) 101 (93; 113) 105 (96; 110)
(mmHg) 6 h 100 (94; 102) 103 (99; 108) 104 (96; 108)
12 h 95 (91; 104) 100 (98; 109) 102 (94; 102)
24 h 92 (89; 98) 102 (99; 107) 95 (93; 106)
36 h 92 (87; 98) 100 (89; 104) 103 (100; 108)
48 h 93 (90; 98) 101 (90; 111) 101(99; 106)
CVP BL 5 (5; 5) 6 (5; 8) 5 (4; 6)
(mmHg) 6 h 7 (6; 11) 9 (7; 10) 9 (8; 10)
12 h 9 (5; 10) 10 (7; 11) 9 (7; 9)
24 h 8 (7; 10) 12 (10; 14)*# 7 (5; 11)
36 h 10 (7; 11) 13 (12; 14)*# 7 (6; 10)†
48 h 9 (9; 11) 11 (7; 13) 6 (5; 8)
LAP BL 7 (6; 8) 9 (8; 10) 9 (9; 10)
(mmHg) 6 h 9 (9; 9) 9 (7; 11) 10 (8; 12)
12 h 12 (11; 12) 11 (9; 13) 11 (9; 12)
24 h 11 (10; 12) 12 (11; 13)* 10 (9; 11)
36 h 12 (9; 13) 14 (13; 16)* 10 (8; 14)
48 h 11 (9; 13) 17 (15; 18)*# 8 (7; 9)†
LVSWI BL 77 (67; 87) 75 (67; 83) 86 (73; 93)
(g/m/m2) 6 h 78 (57; 89) 57 (45; 75) 79 (64; 86)
12 h 66 (64; 72) 50 (44; 60)* 74 (60; 91)
24 h 67 (59; 77) 35 (34; 37)*# 71 (56; 80)†
36 h 71 (65; 76) 35 (31; 43)*# 73 (61; 86)†
48 h 73 (72; 76) 43 (42; 55)*# 66 (63; 73)†
RVSWI BL 13 (13; 14) 12 (10; 15) 13 (11; 15)
(g/m/m2) 6 h 13 (11; 17) 13 (10; 15) 13 (11; 17)
12 h 16 (14; 17) 13 (11; 16) 16 (14; 18)
24 h 15 (15; 17) 9 (8; 11)# 15 (11; 17)
36 h 16 (14; 17) 8 (7; 12)# 13 (13; 17)
48 h 15 (13; 16) 10 (9; 12) 16 (11; 19)
*, P <0.05 vs. BL; #, P <0.05 vs. sham; † , P <0.05 vs. control; data are
represented as median with interquartile range (25th; 75th); each group n = 6
BL, baseline; CI, cardiac index; CVP, central venous pressure; LAP, left atrial
pressure; LVSWI, left ventricular stroke work index; MAP, mean arterial
pressure; rhAT, recombinant human antithrombin III; RVSWI, right ventricular
stroke work index.
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in the present study. Inhibition of p38-MAPK has been
shown to improve myocardial function after burns in
vitro [29] and in rats [27]. An inhibitory effect of AT on
the p38-MAPK pathway, as suggested in the present
study, is supported by an experiment on acute lung
injury in rats [11]. Interestingly, the beneficial effects of
AT in the latter study were abolished, if concomitant
heparin was infused. Since heparin is known to block
the interaction of AT with the syndecan-4 receptor [30],
this mechanism may be involved in the reduction of
p38-MAPK via AT. This hypothesis, however, requires
further verification in future studies.
In accordance with the changes in p38-MAPK expres-
sion, concentrations of TNF-a and IL-6 were lower in
rhAT-treated than in control animals. TNF-a and IL-6
have both been repeatedly reported to correlate with
cardiac contraction and relaxation deficits after burn
trauma [4,31,32] but also in heart failure patients [33].
Myocardial secretion of TNF-a may be directly respon-
sible for an impaired myocardial contractility, reduced
ejection fraction and biventricular dilation [7]. One
mechanism of TNF-a-mediated cardiodepression
includes the induction of NO synthesis [34]. The critical
role of NO in burn- and smoke-induced myocardial dys-
function [8,35] is supported by the biphasic increase in
NOx plasma levels that almost reflect the changes in
SVI in control animals.
Vascular leakage, another hallmark of burn and smoke
inhalation injury, was evidenced by marked decreases in
protein concentration and oncotic pressures in injured
animals. In this context, dilution due to over-resuscita-
tion can be excluded, since hematocrit was maintained
or even increased. Control animals progressively accu-
mulated about 4,000 mL of fluid during the study per-
iod. rhAT-treated animals also had an initial drop in
protein concentration and oncotic pressure that was
probably caused by an irreversible loss via the burn
wound. However, rhAT prevented a progression of pro-
tein leakage and reversed the initial fluid accumulation
resulting in a fluid balance similar to sham animals at
48 h. The clinical relevance of this finding is emphasized
by the correlation of fluid accumulation with negative
outcome not only in burned patients [36] but also in
critical ill patients in general [37]. Since all animals
received the same amount of fluid (after adjustment for
the individual body weight) and there were no differ-
ences in renal function (creatinine clearance) between
groups, these findings suggest a reduction in vascular
leakage by rhAT. This hypothesis is supported by sev-
eral experimental studies reporting beneficial effects of
AT on endothelial function. Potential mechanisms of
action include interactions with the syndecan-4 receptor
[9,26], preservation of the endothelial glycocalyx [38]
and inhibition of endothelial cell activation [39]. The
remaining difference in total urine output between sham
and rhAT-treated animals may be explained by the addi-
tional fluid loss due to evaporation over the burn wound
in the injured rhAT group.
The clinical applicability of the presented therapeutic
approach is potentially limited by the early start of the
infusion, the availability and unwanted side effects of
AT. However, starting AT infusion one hour post-injury
may be feasible, because contrary to most other syn-
dromes patients with burn and smoke inhalation injury
Figure 2 Myocardial oxygen consumption (a) and left ventricular contractility (b). Data are represented as box plots with median and
interquartile range (25th; 75th) (a) or median (b); n = 6 per group. BL, baseline; HR, heart rate; LAP, left atrial pressure; LVSWI, left ventricular
stroke work index; MAP, mean arterial pressure; rhAT, recombinant human antithrombin III.
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are transported to the hospital immediately and can be
diagnosed rapidly. In addition, the recombinant prepara-
tion of AT ensures independence from blood donations
and a reduced risk of transmitted infections. Finally,
based on the present results, there seems to be no
impairment of plasmatic coagulation with the low dose
of 6 IU/kg/h rhAT.
This study has some limitations that we want to
acknowledge. Due to the “two hit” character of the experi-
mental model it is hard to differentiate the effects of rhAT
on the burn-induced changes and the symptoms caused
by smoke inhalation. However, the combined injury is of
high clinical relevance. Another limitation is the estima-
tion of LVSWI by standard formulas and the use of a cor-
relation of LVSWI and LAP as an index of myocardial
contractility, because inotropy should be assessed by load
independent measures. However, these are only available
by echocardiography. To avoid the compromising effects
of anesthetics on myocardial function, the animals were
awake during the experiment necessitating a ventilation
regime that differed from the recommendation of the
acute respiratory distress syndrome (ARDS) network.
Table 2 Hematocrit, plasma protein concentration, oncotic pressure, urine flow, creatinine clearance and antithrombin
plasma levels
Variable Time point sham control rhAT
Hematocrit BL 27 (22; 29) 24 (23; 27) 26 (21; 26)
(%) 6 h 23 (22; 26) 27 (23; 29) 25 (21; 26)
12 h 26 (23; 30) 28 (24; 31) 26 (24; 27)
24 h 25 (24; 27) 30 (27; 32) 27 (22; 27)
36 h 23 (23; 26) 29 (28; 36)*# 27 (27; 28)
48 h 22 (21; 25) 27 (24; 35) 26 (24; 29)
Protein BL 6.1 (6.0; 6.2) 6.2 (5.8; 6.6) 6.1 (6.0; 6.4)
(g/dL) 6 h 5.7 (5.6; 6.0) 4.9 (4.6; 5.0)*# 5.0 (4.6; 5.4)*#
12 h 6.1 (5.9; 6.4) 4.5 (4.4; 4.6)*# 4.9 (4.8; 5.0)*#†
24 h 5.9 (5.8; 6.2) 4.0 (4.0; 4.0)*# 4.6 (4.6; 4.6)*#†
36 h 5.9 (5.7; 6.2) 3.6 (3.6; 3.9)*# 4.7 (4.6; 5.0)*#†
48 h 5.6 (5.6; 5.8) 3.8 (3.5; 3.9)*# 5.0 (4.5; 5.3)*#†
Oncotic pressure BL 19 (17; 20) 19 (18; 20) 20 (19; 22)
(cmH2O) 6 h 18 (16; 19) 13 (12; 14)*
# 14 (13; 16)*#
12 h 18 (16; 20) 12 (11; 13)*# 14 (13; 15)*#
24 h 19 (16; 20) 10 (9; 10)*# 13 (12; 14)*#†
36 h 19 (16; 20) 9 (9; 11)*# 13 (13; 15)*#†
48 h 17 (15; 18) 9 (9; 10)*# 13 (12; 15)*#†
Urine flow BL / / /
(mL/kg/h) 6 h 7.7 (6.8; 8.3) 3.4 (2.5; 4.3)# 3.2 (1.6; 4.7)#
12 h 7.4 (4.5; 9.0) 2.7 (2.0; 4.5)# 2.7 (2.4; 3.8)#
24 h 4.5 (2.7; 5.7) 1.2 (1.1; 2.0)# 4.0 (3.0; 5.2)†
36 h 2.3 (2.0; 2.9) 0.6 (0.3; 0.8)# 4.1 (3.7; 5.4)#†
48 h 2.4 (2.1; 2.5) 0.8 (0.8; 0.9)# 3.3 (2.6; 3.8)†
Creatinine clearance BL / / /
(mL/min) 6 h / / /
12 h 105 (97; 129) 89 (78; 141) 78 (76; 124)
24 h 88 (78; 176) 84 (71; 94) 100 (91; 115)
36 h 107 (84; 135) 104 (74; 122) 120 (106; 134)
48 h 102 (81; 112) 91 (88; 94) 96 (82; 115)
AT plasma level BL 86 (83; 89) 79 (72; 82) 87 (73; 93)
(mg/L) 6 h 86 (81; 89) 58 (57; 59)*# 88 (83; 89)†
12 h 87 (83; 91) 52 (50; 55)*# 85 (81; 95)†
24 h 86 (73; 88) 45 (40; 50)*# 83 (75; 84)†
36 h 86 (76; 88) 47 (40; 48)*# 86 (80; 87)†
48 h 83 (75; 88) 52 (47; 54)*# 84 (73; 87)†
*, P <0.05 vs. BL; #, P <0.05 vs. sham; † , P <0.05 vs. control; data are represented as median with interquartile range (25th; 75th); each group n = 6
AT, antithrombin; BL, baseline; rhAT, recombinant human antithrombin III
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Finally, the smoke arising from house or industrial fires
contains a multitude of toxic gases potentially resulting in
differences in lung injury compared with the cotton
smoke tested in the present study.
Conclusions
In summary, this is the first study demonstrating therapeu-
tic effects of rhAT substitution on myocardial dysfunction
and inflammation as well as systemic fluid accumulation
following burn and smoke inhalation injury in a clinically
relevant animal model. Based on these findings, the supple-
mentation of rhAT may represent a potential therapeutic
approach for burn- and smoke inhalation-induced cardio-
vascular dysfunction.
Key messages
• Combined burn and smoke inhalation injury is
associated with a marked myocardial dysfunction.
To compensate for the reduced stroke volume, heart
rate and eventually myocardial oxygen consumption
are increased.
• Impairment of myocardial function after burn and
smoke inhalation injury is characterized by an
activation of the p38-mitogen-activated protein kinase
pathway, myocardial neutrophil accumulation and
increased nitric oxide production.
• The therapeutic infusion of recombinant human
antithrombin restored myocardial function to the level
of sham (not injured) animals, resulting in higher stroke
volumes and reduced myocardial oxygen consumption.
• The therapeutic infusion of recombinant human
antithrombin reversed cumulative systemic fluid accu-
mulation back to the level of sham animals at 48 h.
• The attenuated inflammatory response, as sug-
gested by a reduced activation of the p38-mitogen-
activated protein kinase pathway resulting in lower
cytokine release, less myocardial neutrophil accumu-
lation and less nitric oxide production, presents a
potential mechanism of action.
Additional material
Additional file 1: Supplemental file (word): detailed Materials and
methods. This file provides detailed information about the
instrumentation, mechanical ventilation, hemodynamic monitoring,
Western blots as well as laboratory and immunohistochemical analyses.
Figure 3 Cumulative net fluid balance (a) and concentration of NOx in the plasma (b). *P <0.05 vs. baseline; #P <0.05 vs. sham; † P <0.05
vs. control; data are represented as box plots with median and interquartile range (25th; 75th); n = 6 per group. BL, baseline; NOx, nitrates and
nitrites; rhAT, recombinant human antithrombin III.
Table 3 Immunohistochemical analyses and Western blots
Variable sham control rhAT
Myeloperoxidase activity (U/mL) 105 (104; 106) 132 (120; 139)# 114 (105; 118)†
p38-MAPK (arbitrary units) 2.3 (1.8; 3.5) 6.1 (5.4; 6.5)# 2.8 (2.3; 3.0)†
TNF-a (arbitrary units) 2.1 (1.8; 2.1) 2.7 (2.6; 2.8)# 2.0 (1.6; 2.4)†
IL-6 (arbitrary units) 1.4 (1.3; 2.0) 4.0 (3.0; 4.6)# 2.1 (1.9; 2.8)†
#, P <0.05 vs. sham; † , P <0.05 vs. control; data are represented as median with interquartile range (25th; 75th); each group n = 6
IL-6, interleukin 6; p38-MAPK, p38-mitogen-activated protein kinases; rhAT, recombinant human antithrombin III; TNF-a, tumor necrosis factor alpha.
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Additional file 2: Supplemental file (word): additional data. This file
provides additional data that may be of interest for the reader, but
where not relevant in respect to the message of the study.
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syndrome; SVI: stroke volume index; TNF-α: tumor necrosis factor-alpha
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